Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MAGNE-B6 Oral Solution
MAGNE-B6 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment Sequence Group 1 | EXPERIMENTAL | - |
| Treatment Sequence Group 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MAGNE-B6 Oral Solution | DRUG | Oral solution. |
| MAGNE-B6 New Formulation Tablet | DRUG | New formulation tablet. |
Inclusion Criteria: 1. Male or female participants, between 18 and 45 years of age, inclusive. 2. Body weight between 50.0 and 100.0 kg, inclusive, if male, and between 40.0 and 90.0 kg, inclusive, if female, body mass index (BMI) between 18.0 and 30.0 kilogram per square meter (kg/m\^2), inclusive...
MAGNE-B6 is an investigational small molecule developed by Sanofi. It is also known as MAGNE-B6 Oral Solution. The program is in Phase 1 clinical development, and the specific therapeutic indication has not been disclosed. One Phase 1 trial of the drug has been completed.
MAGNE-B6 is developed by Sanofi, which trades under the ticker SNY. Sanofi is the sponsor of the clinical program for the drug, including the completed Phase 1 bioavailability study conducted in healthy volunteers.
MAGNE-B6 is in Phase 1 clinical development. One Phase 1 trial has been completed and no trials are currently active. The program has not been approved for any indication, and the therapeutic area is listed as other with the indication undisclosed.
MAGNE-B6 has been studied in one completed Phase 1 trial, NCT06386211, titled Bioavailability Study of Magne-B6 New Formulation. The trial enrolled 24 healthy volunteers aged 18 years and older in Turkey (Türkiye). It was randomized and controlled, with no double-blind design.
Yes, MAGNE-B6 Oral Solution is an alternative name for MAGNE-B6. Both names refer to the same Sanofi investigational small molecule in Phase 1 development, so readers searching either name are looking at the same drug asset and the same clinical program.